Novo Nordisk eyes technology tie-ups

The world's top insulin producer by sales is confident that China's focus on innovation will spur it toward new partnerships with local entrepreneurs for technology solutions to complement modern treatments for diabetics, said Jakob Riis, executive vice-president of China and Pacific & marketing, Novo Nordisk A/S.

The Copenhagen-based company has been operating in China for 22 years and is the market leader, Riis told China Daily on the sidelines of the Summer Davos in Tianjin on Monday.

Novo Nordisk boasts the largest share of 30 percent in China's 21.3-billion-yuan ($3.2-billion) diabetes-related drugs market.